{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:45:01Z","timestamp":1771508701189,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,9,13]],"date-time":"2013-09-13T00:00:00Z","timestamp":1379030400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s10072-013-1536-0","type":"journal-article","created":{"date-parts":[[2013,9,12]],"date-time":"2013-09-12T07:34:26Z","timestamp":1378971266000},"page":"429-435","source":"Crossref","is-referenced-by-count":9,"title":["A prospective, open-label study of milnacipran in the prevention of headache in patients with episodic or chronic migraine"],"prefix":"10.1007","volume":"35","author":[{"given":"Emily Rubenstein","family":"Engel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Kudrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan M.","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,9,13]]},"reference":[{"key":"1536_CR1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1046\/j.1526-4610.2001.041007646.x","volume":"41","author":"RB Lipton","year":"2001","unstructured":"Lipton RB, Stewart WF, Diamond S et al (2001) Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41:646\u2013657","journal-title":"Headache"},{"issue":"5","key":"1536_CR2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1526-4610.1976.hed1605238.x","volume":"16","author":"B Forssman","year":"1976","unstructured":"Forssman B, Henriksson K-G, Johannsson V et al (1976) Propranolol for migraine prophylaxis. Headache 16(5):238\u2013245","journal-title":"Headache"},{"issue":"18","key":"1536_CR3","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1001\/jama.1984.03350180030025","volume":"252","author":"S Stellar","year":"1984","unstructured":"Stellar S, Ahrens SP, Meibohm AR et al (1984) Migraine prevention with timolol: a double-blind crossover study. JAMA 252(18):2576\u20132580","journal-title":"JAMA"},{"key":"1536_CR4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1468-2982.1992.1202081.x","volume":"12","author":"R Hering","year":"1992","unstructured":"Hering R, Kuritzky A (1992) Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 12:81\u201384","journal-title":"Cephalalgia"},{"issue":"8","key":"1536_CR5","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/jama.291.8.965","volume":"291","author":"JL Brandes","year":"2004","unstructured":"Brandes JL, Saper JR, Diamond M et al (2004) Topiramate for migraine prevention. A randomized, controlled trial. JAMA 291(8):965\u2013973","journal-title":"JAMA"},{"key":"1536_CR6","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","volume":"278","author":"SD Silberstein","year":"2012","unstructured":"Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E, Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society (2012) Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 278:1337\u20131345","journal-title":"Neurology"},{"key":"1536_CR7","doi-asserted-by":"crossref","first-page":"E269","DOI":"10.1503\/cmaj.081657","volume":"182","author":"T Pringsheim","year":"2010","unstructured":"Pringsheim T, Davenport WJ, Becker WJ (2010) Prophylaxis of migraine headache. CMAJ 182:E269\u2013E276","journal-title":"CMAJ"},{"issue":"7","key":"1536_CR8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1533-2500.2012.00530.x","volume":"12","author":"A Berger","year":"2012","unstructured":"Berger A, Bloudek LM, Varon SF, Oster G (2012) Adherence with migraine prophylaxis in clinical practice. Pain Pract 12(7):541\u2013549","journal-title":"Pain Pract"},{"key":"1536_CR9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/PROM.S9742","volume":"1","author":"M Pompili","year":"2010","unstructured":"Pompili M, Serafini G, Innamorati M et al (2010) Patient outcome in migraine prophylaxis: the role of psychopharmacological agents. Patient Relat Outcome Meas 1:107\u2013118","journal-title":"Patient Relat Outcome Meas"},{"issue":"1","key":"1536_CR10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.clineuro.2004.03.004","volume":"107","author":"S Bulut","year":"2004","unstructured":"Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B (2004) Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 107(1):44\u201348","journal-title":"Clin Neurol Neurosurg"},{"issue":"2","key":"1536_CR11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1526-4610.2005.05029.x","volume":"45","author":"SN Ozyalcin","year":"2005","unstructured":"Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R (2005) The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 45(2):144\u2013152","journal-title":"Headache"},{"key":"1536_CR12","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3899\/jrheum.080734","volume":"36","author":"PJ Mease","year":"2009","unstructured":"Mease PJ, Clauw DJ, Gendreau RM et al (2009) The efficacy and safety of milnacipran for treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. J Rheumatol 36:398\u2013409","journal-title":"J Rheumatol"},{"key":"1536_CR13","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3899\/jrheum.090884","volume":"37","author":"JC Branco","year":"2010","unstructured":"Branco JC, Zachrisson D, Perrot S et al (2010) A European multicenter randomized double-blind, placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. J Rheumatol 37:851\u2013859","journal-title":"J Rheumatol"},{"key":"1536_CR14","first-page":"15","volume":"3","author":"M Ormseth","year":"2010","unstructured":"Ormseth M, Eyler A, Hammonds C et al (2010) Milnacipran for the management of fibromyalgia syndrome. J Pain Res 3:15\u201324","journal-title":"J Pain Res"},{"key":"1536_CR15","unstructured":"US FDA. Good Clinical Practice Guidelines. Available at: http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/OfficeofScienceandHealthCoordination\/ucm2018191.htm . Accessed July 17, 2013"},{"key":"1536_CR16","unstructured":"World Medical Association. Declaration of Helsinki. Available at: http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/ . Accessed July 17, 2013"},{"key":"1536_CR17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0304-3959(00)00305-5","volume":"88","author":"WF Stewart","year":"2000","unstructured":"Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN (2000) Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 88:41\u201352","journal-title":"Pain"},{"key":"1536_CR18","unstructured":"Beck AT, Steer RA (1987) The Beck Depression Inventory manual San Antonio: The Psychological Corporation, Harcourt Brace Jovanovich"},{"key":"1536_CR19","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","volume":"14","author":"M Johns","year":"1991","unstructured":"Johns M (1991) A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 14:540\u2013545","journal-title":"Sleep"},{"issue":"(4 Suppl)","key":"1536_CR20","first-page":"AS264","volume":"33","author":"JE Ware Jr","year":"1995","unstructured":"Ware JE Jr, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A et al (1995) Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 33((4 Suppl)):AS264\u2013AS279","journal-title":"Med Care"},{"issue":"Suppl 4","key":"1536_CR21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00004850-199609004-00006","volume":"11","author":"J Lopez-Ibor","year":"1996","unstructured":"Lopez-Ibor J, Guelfi JD, Pletan Y et al (1996) Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 11(Suppl 4):41\u201346","journal-title":"Int Clin Psychopharmacol"},{"issue":"Suppl 1","key":"1536_CR22","first-page":"23","volume":"6","author":"S Kasper","year":"2010","unstructured":"Kasper S, Pail G (2010) Milnacipran: a unique antidepressant? Neuropsychiatr Dis Treat 6(Suppl 1):23\u201331","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1536_CR23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1744-8069-8-45","volume":"8","author":"T Kohno","year":"2012","unstructured":"Kohno T, Kimura M, Sasaki M et al (2012) Milnacipran inhibits glutamatergic N-Methyl-D-Aspartate receptor activity in Spinal Dorsal Horn Neurons. Mol Pain 8:45","journal-title":"Mol Pain"},{"key":"1536_CR24","unstructured":"Effexor [package insert] (2013) Wyeth Pharmaceuticals, Philadelphia, PA"},{"issue":"6","key":"1536_CR25","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/sj.bjp.0707253","volume":"151","author":"PK Gilman","year":"2007","unstructured":"Gilman PK (2007) Tricyclic antidepressant pharmacology and therapeutic drug interaction. Br J Pharmacol 151(6):737\u2013748","journal-title":"Br J Pharmacol"},{"key":"1536_CR26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/1759720X10372551","volume":"2","author":"RH Palmer","year":"2010","unstructured":"Palmer RH, Periclou A, Banerjee P (2010) Milnacipran: a selective serotonin and norepinephrine dual reuptake inhibitor for the management of fibromyalgia. Ther Adv Musculoskelet Dis 2:201\u2013220","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1536_CR27","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2147\/NDT.S33769","volume":"9","author":"E Estemalik","year":"2013","unstructured":"Estemalik E, Tepper S (2013) Preventive treatment in migraine and the new US guidelines. Neuropsychiatr Dis Treat 9:709\u2013720","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1536_CR28","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1523\/JNEUROSCI.13-03-01167.1993","volume":"13","author":"MA Moskowitz","year":"1993","unstructured":"Moskowitz MA, Nozaki K, Kraig RP (1993) Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within the trigeminal nucleus caudalis via trigeminovascular mechanisms. J Neurosci 13:1167\u20131177","journal-title":"J Neurosci"},{"key":"1536_CR29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/jcbfm.1992.32","volume":"12","author":"M Lauritzen","year":"1992","unstructured":"Lauritzen M, Hansen AJ (1992) The effect of Glutamate Receptor Blockade on anoxic depolarization and cortical spreading depression. J Cereb Blood Flow Metab 12:223\u2013229","journal-title":"J Cereb Blood Flow Metab"},{"issue":"2","key":"1536_CR30","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1124\/jpet.106.117101","volume":"321","author":"M Peeters","year":"2007","unstructured":"Peeters M, Gunthorpe MJ, Strijbos PJ et al (2007) Effects of pan- and Subtype-selective N-methyl-D-aspartate receptor antagonists on cortical spreading depression in the rat: therapeutic potential for migraine. J Pharmacol Exp Ther 321(2):564\u2013572","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-013-1536-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-013-1536-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-013-1536-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T20:52:57Z","timestamp":1563915177000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-013-1536-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,13]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["1536"],"URL":"https:\/\/doi.org\/10.1007\/s10072-013-1536-0","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,13]]}}}